Brief: Briacell Enters Definitive Arrangement Agreement For Spin Out Of Briapro Therapeutics Corp.
25/05/2023 14:15
May 25 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL THERAPEUTICS - CERTAIN PRE-CLINICAL PIPELINE
ASSETS
INCLUDING BRIA-TILSRX, PROTEIN KINASE C DELTA INHIBITORS TO BE
SPUN-OUT
* BRIACELL ENTERS DEFINITIVE ARRANGEMENT AGREEMENT FOR THE
SPIN
OUT OF BRIAPRO THERAPEUTICS CORP.
* BRIACELL THERAPEUTICS CORP- ENTERED INTO AN ARRANGEMENT
AGREEMENT DATED MAY 24, 2023 WITH BRIAPRO THERAPEUTICS CORP.
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study